Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Insulet

NASDAQ: PODD ↗$147.48 USD~$22B MCAP
#Diabetes#Insulin Delivery#Chronic Disease Management

Insulet Corporation is a medical device company best known for its Omnipod insulin management system, the only tubeless insulin pump available in the U.S. Insulet is expanding into adjacent chronic disease management through technology partnerships.

Company Info

Sector:Medical Devices / Diabetes
Headquarters:Acton, Massachusetts, USA
Founded:2000
Website:www.omnipod.com/

Upcoming Milestones & Key Dates

2026-Q4
Commercial

Continued U.S. and international Omnipod 5 rollout

Clinical Development Pipeline

Omnipod 5

Target: Tubeless insulin pump with CGM integration
Type 1 and Type 2 diabetes (automated insulin delivery)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Omnipod 5 + Abbott FreeStyle Libre integration

Target: iCGM-compatible tubeless pump
Type 1 diabetes
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Omnipod for GLP-1 users

Target: Insulin pump for combination therapy
Type 2 diabetes on GLP-1 therapy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Jim Hollingshead

President & CEO

Wayde McMillan

Chief Financial Officer

Eric Benjamin

EVP, Innovation & Strategy

Careers & Job Openings

See all open roles

Multiple Departments
Acton, Massachusetts, USA
Apply Now →